Supernus Pharmaceuticals (SUPN) Total Non-Current Liabilities (2016 - 2025)
Historic Total Non-Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $358.6 million.
- Supernus Pharmaceuticals' Total Non-Current Liabilities rose 2428.27% to $358.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $358.6 million, marking a year-over-year increase of 2428.27%. This contributed to the annual value of $285.0 million for FY2024, which is 584.96% down from last year.
- Per Supernus Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $358.6 million for Q3 2025, which was up 2428.27% from $310.7 million recorded in Q2 2025.
- Supernus Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $826.3 million during Q1 2023, with a 5-year trough of $285.0 million in Q4 2024.
- In the last 5 years, Supernus Pharmaceuticals' Total Non-Current Liabilities had a median value of $358.6 million in 2025 and averaged $522.1 million.
- Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 2471.31% in 2021, then tumbled by 6096.4% in 2024.
- Supernus Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $792.8 million in 2021, then dropped by 3.97% to $761.3 million in 2022, then crashed by 60.24% to $302.7 million in 2023, then decreased by 5.85% to $285.0 million in 2024, then grew by 25.84% to $358.6 million in 2025.
- Its Total Non-Current Liabilities stands at $358.6 million for Q3 2025, versus $310.7 million for Q2 2025 and $286.6 million for Q1 2025.